Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic.
Sanofi and Regeneron’s Praluent cholesterol drug has been approved in the US to help prevent cardiovascular events, a new indication that will help it compete with Amgen’s rival from the sa
A new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group of new drugs that look set for the European market following backing from regulators.
Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling.
